AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a Conversation About an...
September 20 2018 - 9:15AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that
together with Emmy®-nominated actress Cheryl Hines and leading
family medicine and menopause expert, Marla Shapiro, MD, it is
launching an integrated campaign to start an open dialogue about
painful sex due to menopause, a topic that is often not talked
about among post-menopausal women and their healthcare providers.
Vulvar and vaginal atrophy, or VVA, affects approximately 50
percent of postmenopausal women in the United States, and painful
sex is one of the potential symptoms.1 Unlike more commonly known
symptoms of menopause, such as hot flashes, many women are not
aware that painful sex is associated with menopause. This is
further compounded by the fact that women are generally not
comfortable talking about these symptoms with their partners,
healthcare providers or friends. Through this campaign and other
educational efforts, AMAG, Hines and Dr. Shapiro hope to give women
the tools they need to recognize this condition and have a
conversation with their healthcare provider about treatment
options.
“Painful sex due to menopause is not an inevitable part of
aging,” said Hines. “As women, we go through so many emotional and
physical changes over the course of our lifetime. Before puberty
and childbirth, we are prepared by our family members and
healthcare providers about what to expect, but that isn’t the
case with menopause. Painful sex due to menopause is often
considered a taboo topic and I want to change that. I want to
help be a voice for those women, including my friends that are
living with it, and to help educate women, like me, who may
experience this condition in the future. That’s why I am
starting an open, honest and even light-hearted dialogue about this
condition. Let’s get a conversation started and take away the
shroud of secrecy that is often associated with painful sex due to
menopause.”
“This condition took a toll on my relationship and eroded my
self-confidence,” said Traciee, who suffered with painful sex due
to menopause and shares her story as part of AMAG’s SHE Network.
“It took me three years to get prescription treatment that gave me
meaningful pain relief. I don’t want other women to go through what
I did so now I’m talking to my friends, family and even the ladies
at my church about this condition and encouraging them to speak to
their healthcare providers.”
After menopause, hormonal changes can lead to VVA which causes a
variety of physical changes to the vagina, such as the loss of
vaginal tissue, lubrication, and flexibility. All of these changes
can lead to symptoms like dryness, irritation, frequent urination,
and painful sex. However, most women do not know what is causing
their symptoms. According to survey data, 62 percent of
post-menopausal women were not familiar with the condition of VVA,
and even among those who were aware, only half became aware after
they began to experience symptoms.2
“Unlike other menopause symptoms like hot flashes and night
sweats painful sex will not get better without treatment, and often
it will get worse,” said Dr. Shapiro, Professor of Family and
Community Medicine at the University of Toronto. "Over-the-counter
treatments like lubricants and moisturizers do not address the
underlying cause of the condition and may not provide adequate pain
relief for women with moderate to severe pain. I both encourage and
urge women to talk to their healthcare providers and learn about
available prescription treatment options that directly target VVA
symptoms.”
To learn more about painful sex due to menopause including
treatment options and a guide to discussing this condition with
your healthcare provider, please visit www.PauseSexPain.com. There
you will also learn more about the campaign including videos
featuring Hines and Dr. Shapiro.
About AMAGAMAG is a pharmaceutical company
focused on bringing innovative products to patients with unmet
medical needs. The company does this by leveraging its development
and commercial expertise to invest in and grow its pharmaceutical
products across a range of therapeutic areas, including women’s
health. In addition, AMAG seeks to collaborate on and acquire
promising therapies at various stages of development, and advance
them through the clinical and regulatory process to deliver new
treatment options to patients. For additional company information,
please visit www.amagpharma.com.
Forward Looking Statements
This press release contains forward-looking information about
AMAG within the meaning of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Any statements
contained herein which do not describe historical facts, including,
among others, the ability of the campaign to help women recognize
the condition and empower them to talk to their healthcare
providers about treatment options are based on management’s current
expectations and beliefs and are forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include those risks identified in
AMAG’s filings with the U.S. Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended
December 31, 2017, its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2018 and subsequent filings with the SEC,
which are available at the SEC’s website at www.sec.gov. Any such
risks and uncertainties could materially and adversely affect
AMAG’s results of operations, its profitability and its cash flows,
which would, in turn, have a significant and adverse impact on
AMAG’s stock price. AMAG cautions you not to place undue reliance
on any forward-looking statements, which speak only as of the date
they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc.
CONTACTS: Investors: Linda Lennox
908-627-3424
Media: Sarah Connors781-296-0722
1 Wysocki et al. Management of Vaginal Atrophy: Implications
from the REVIVE Survey. Clinical Medicine Insights: Reproductive
Health 2014:8 23–30 doi:10.4137/CMRH.S14498.
2 Kingsberg et al. “Vulvar and Vaginal Atrophy in Postmenopausal
Women: Findings from the REVIVE (REal Women’s Views of Treatment
Options for Menopausal Vaginal ChangEs) Survey.” J Sex Med 2013;
10:1790-1799.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/7e110c2d-d139-43c4-b531-c99dbd9056f4
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024